TCR² is a clinical-stage immunotherapy company developing a new generation of T cell therapies for patients suffering from cancer.
STA Research Full Report:STA-TCRR-2019-03-12
TCR2(TCRR) Therapeutics Inc, initiated with $30.75 average Target.
STA Research
March 12th, 2019
Top Trending Stocks
| AVG Analyst Rating | STA Analysis | |
|---|---|---|
Strong Buy
|
Very Bullish
|
|
Strong Buy
|
Slightly Bearish
|
|
Strong Buy
|
Very Bullish
|
|
| N/A | N/A | |
| N/A |
Neutral
|
|
|
Strong Buy
|
Neutral
|
|
|
Strong Buy
|
Very Bullish
|
|
Strong Buy
|
Bullish
|
|
Strong Buy
|
Slightly Bullish
|
|
|
Strong Buy
|
Slightly Bearish
|
